A Phase 2 interventional study of Gemeprost 1 Mg Vaginal Pessary and Dinoprostone 3 mg in Missed Abortion, Medical; Abortion, Fetus and Incomplete Abortion, sponsored by National University of Malaysia. Completed at 2 sites in Malaysia. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.
Sponsored by National University of Malaysia · Phase 2, Interventional, and Treatment
Comparison between gemeprost and dinoprostone to evacuate first trimester miscarriages.
Women who are diagnosed with first trimester missed miscarriages are invited to participate in the study. They will be randomised to either gemeprost or dinoprostone.
48 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.
This study's enrollment of 101 is close to the median of 110 across 41 interventional studies indexed under Abortion, Missed.
Browse Abortion, Missed studies →National University of Malaysia is the lead sponsor of 124 studies on the registry; 45 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
Drug: Gemeprost 1 Mg Vaginal Pessary · Drug: Dinoprostone 3 mg
Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
Drug: Gemeprost 1 Mg Vaginal Pessary · Drug: Dinoprostone 3 mg
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
Percentage of women who achieved complete evacuation
Complete expulsion of product of conception
Time frame: from recruitment until up to one week after commencement of treatment
Percentage of women who experienced side effects
side effects towards each drug such as fever, gastrointestinal upset
Time frame: from recruitment until up to one week after commencement of treatment
Plan to share: Undecided — Yes
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dinoprostone
National University of Malaysia →